Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

INTRODUCTION: Brodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargiulo, Luigi, Ibba, Luciano, Malagoli, Piergiorgio, Amoruso, Fabrizio, Argenziano, Giuseppe, Balato, Anna, Bardazzi, Federico, Burlando, Martina, Carrera, Carlo Giovanni, Damiani, Giovanni, Dapavo, Paolo, Dini, Valentina, Fabbrocini, Gabriella, Franchi, Chiara, Gaiani, Francesca Maria, Girolomoni, Giampiero, Guarneri, Claudio, Lasagni, Claudia, Loconsole, Francesco, Marzano, Angelo Valerio, Megna, Matteo, Sampogna, Francesca, Travaglini, Massimo, Costanzo, Antonio, Narcisi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352451/
https://www.ncbi.nlm.nih.gov/pubmed/37469659
http://dx.doi.org/10.3389/fmed.2023.1196966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352451/
https://www.ncbi.nlm.nih.gov/pubmed/37469659
http://dx.doi.org/10.3389/fmed.2023.1196966

Ejemplares similares